This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Here's Why Aegerion and Sarepta Trade Higher Wednesday

A quick word on two stocks -- Aegerion Pharmaceuticals (AEGR - Get Report) and Sarepta Therapeutics (SRPT - Get Report) -- both trading higher Wednesday.

Aegerion reported Juxtapid sales of $36 million in the second quarter, a hair higher than the Street's $35 million consensus estimate. More importantly, Aegerion refined its 2014 Juxtapid sales guidance to the lower end of the previous $180-200 million range. Why is the market viewing this positively? Because many investors expected Aegerion to lower 2014 Juxtapid sales guidance. (Current consensus estimate is $173 million.) The company surprised by sticking with current guidance, which the market is viewing favorably Wednesday. 

There's still plenty of skepticism about Aegerion's ability to deliver $180 million in Juxtapid sales this year. First half Juxtapid sales totaled $63 million, which means Aegerion has to step up and deliver $117 million in sales in the next two quarters. The company believes it can get there with continued growth in U.S. sales combined with an improved outlook in Brazil, where current quarter sales already surpassing second-quarter sales. 

Aegerion shares were up 17% to $35.73 in recent trading.

Sarepta shares are reacting to the posting of an FDA response to a White House petition submitted by Duchenne muscular dystrophy families calling for speedy approval of new drugs. The FDA response to the petition was penned by Janet Woodcock, director of FDA Center for Drug Evaluation and Research. Among other points, Woodcock says:

We are willing to explore the use of all potential pathways for the approval of drugs for Duchenne muscular dystrophy, including accelerated approval, as appropriate. We share your sense of urgency to make safe and effective drugs available for patients with Duchenne muscular dystrophy as soon as possible. That's why we're actively engaged with a number of drug companies focused on developing new drugs for Duchenne muscular dystrophy, including Sarepta Therapeutics, the company developing eteplirsen, an investigational new drug for Duchenne muscular dystrophy.

Sarepta shares are up 13% to $23.04.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AEGR $25.94 -0.38%
SRPT $13.87 2.20%
AAPL $126.37 2.53%
FB $83.20 -0.13%
GOOG $552.03 0.67%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs